|
Global Vaccines Market 2010-2025Übersetzung: Globaler Impfstoff Markt 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
206 seiten | |||||||||||
| Inhalt der Studie: |
In 2009, the global market for vaccines achieved sales of over $10bn. Hundreds of millions of people are affected by infectious diseases that can be fought by vaccination. Despite controversy, vaccine.....
In 2009, the global market for vaccines achieved sales of over $10bn. Hundreds of millions of people are affected by infectious diseases that can be fought by vaccination. Despite controversy, vaccine use remains one of the greatest successes in the fight against disease - one with a long history. This market will achieve sustained growth over the next 15 years, our new study reveals. Increasingly, governments recognize the benefits of mass vaccination, with successive vaccines delivering healthcare solutions on a large scale, a trend set to continue. Global Vaccines Market 2010-2025 provides a detailed analysis of the human vaccines market, predicting how and why it will expand in coming years. Our study provides a detailed forecast of the existing market, dividing it into major groups, from pediatric vaccines to prophylactic cancer treatments. Our report shows the commercial potential of vaccine classes from 2010 to 2025. We examine the most-successful current vaccines in particular, forecasting their sales and discussing their prospects in detail. Which vaccines will achieve blockbuster sales from 2010 onwards? Which classes will experience the fastest growth, and what will cause this market expansion? What are the greatest unmet needs in vaccine use? What are the principal market drivers and restraints? What conditions are most likely to benefit from vaccine solutions in future, especially disorders currently un-served or under-served by treatments? This report covers those and other crucial questions, providing the information that you need. Our new study examines the biotechnological possibilities, determining which companies and which products are best placed to succeed in the vaccines market. Comprehensive analysis of the global vaccines market Global Vaccines Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 75 tables and figures included, as well as three original interviews with relevant experts. The result is a comprehensive market- and industry-centered study, with detailed analyses and informed opinion to benefit your work. Nobody with an interest in the vaccines sector should overlook this new study. We predict that total revenues will increase. Recent technological advances have led to high expectations for vaccines currently in development. With rising demand worldwide and currently-unmet needs, this market holds significant potential for technological innovation and revenue growth. Report Highlights Companies Listed ALK-Abelló Acambis Accentia ACE Biosciences Advisory Committee on Immunization Practices (ACIP) Aeras Global TB Vaccine Foundation AFFiRiS Aflunov AlphaVax Allergy Therapeutics AnGes MG Astellas AstraZeneca Avax Technologies Australian Therapeutic Goods Administration (TGA) Barr Bavarian Nordic Baxter International BD, Bector, Dickinson & Co. Bharat Biotech Bill & Melinda Gates Foundation BioDiem Biogen Idec Bioject Biondvax Pharmaceuticals Biotecnol Cambridge Biostability Centers for Disease Control (CDC) Celldex Celtic Pharma China National Biotec Group Chinese State Food and Drug Administration (SFDA) Chiron Crucell CSL Limited Cytos Biotechnology Daiichi-Sankyo Dendreon Department of Health and Human Services (HHS) Diamyd Medical DynPort Vaccine Company Dynavax Elan EMEA Emergent BioSolutions FDA (US) Food and Drug Administration in Thailand (TFDA) Genelabs Genetic Immunity GenVec Geron Green Cross GlaxoSmithKline (GSK) GlobeImmune Independent Pharmaceutica Inovio Biomedical Intercell International AIDS Vaccine Initiative (IAVI) Johnson & Johnson Karolinska Institutet LigoCyte LipoNova Lonza Ludwig Institute for Cancer Research MedImmune Menarini Merck & Co Merck KGaA Mitsubishi Tanabe Pharma Nabi Biopharmaceuticals NasVax National Institute of Allergy and Infectious Diseases (NIAID) NIAI NIAID Vaccine Research Center Nobilon Novartis Novavax Oncothyreon Oxford BioMedica PepTcell Petrovax Pfizer PharmAthene Pharmexa Protein Sciences Ranbaxy Roche Sanofi Aventis Sanofi Pasteur MSD Schering-Plough Serum Institute of India Sinovac Solvay Statens Serum Institute of Denmark (SSI) Takeda Targeted Genetics Teva Thai Ministry of Public Health Transgene Tripep UMN Pharma UNICEF University of Queensland, Australia University of Virginia School of Medicine UK Defence Science and Technology Laboratory (Dstl) US Army US Department of Health and Human Services (HHS) Vaccine Technologies Vaccinogen VaxGen Vaxine Vical Virax World Health Organisation (WHO) Wistar Institute Wyeth [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Vaccines Market Review 1.2 Overview of Report Content and Methods Used 2. Vaccines and Vaccine-Preventable Diseases 2.1 Immunisation and Types of Vaccine 2.1.1 Vaccines: a Healthcare Triumph 2.1.2 The Immune System and Natural Immunity 2.1.3 Edward Jenner Laid the Foundation for Modern Vaccines 2.1.4 Vaccines Work by Creating Artificial Immunity 2.1.5 Vaccine Formulation 2.1.6 Types of Vaccine 2.1.7 Live Attenuated Vaccines 2.1.8 Recombinant Live Vaccines 2.1.9 Inactivated Vaccines 2.1.10 Toxoid Vaccines 2.1.11 Conjugate Vaccines 2.1.12 Recombinant Subunit Vaccines 2.1.13 DNA Vaccines 2.1.14 Recombinant Vector Vaccines 2.2 Vaccine-Preventable Diseases 2.2.1 Chickenpox and Shingles 2.2.2 Cholera 2.2.3 Diphtheria 2.2.4 Haemophilus Influenzae Type b (Hib) Diseases 2.2.5 Hepatitis A 2.2.6 Hepatitis B 2.2.7 Human Papillomavirus (HPV) - Cervical Cancer 2.2.8 Influenza 2.2.9 Seasonal Influenza 2.2.10 Pandemic Influenza 2.2.11 Influenza Vaccination 2.2.12 Japanese Encephalitis 2.2.13 Measles 2.2.14 Neisseria Meningitidis - Meningococcal Diseases 2.2.15 Mumps 2.2.16 Pertussis 2.2.17 Polio 2.2.18 Rabies 2.2.19 Rotavirus Infections 2.2.20 Rubella 2.2.21 Streptococcus Pneumoniae Infections 2.2.22 Tetanus 2.2.23 Tick-Borne Encephalitis 2.2.24 Tuberculosis 2.2.25 Typhoid 2.2.26 Yellow Fever 3. The Global Vaccines Market, 2010-2025 3.1 Global Vaccines Market, 2009 3.1.1 Vaccine Types 3.1.2 Leading Vaccine Types 3.1.3 Leading Vaccine Brands 3.1.4 Leading Vaccine Manufacturers 3.2 Global Vaccine Market Forecast, 2010-2025 3.2.1 Total Market Tables and Figures 3.2.2 The Market by Subdivisions: Tables and Figures 3.2.3 World Vaccine Market Growth 3.2.4 The World Vaccine Market: Fastest- and Slowest-Growing Categories 3.3 Paediatric Vaccines 3.3.1 Leading Paediatric Vaccine Brands, 2009 3.3.2 Leading Paediatric Vaccine Manufacturers, 2009 3.3.3 Paediatric Vaccine Market Share will Slide? 3.3.4 Varivax (Merck & Co/Sanofi Pasteur MSD) 3.3.5 M-M-R II (Merck & Co/Sanofi Pasteur) 3.3.6 ProQuad (Merck & Co) 3.3.7 Varivax/M-M-R-II/ProQuad Sales Analysis, 2009 3.3.8 Varivax/M-M-R-II/ProQuad Sales Forecast, 2010-2015 3.3.9 Prevnar/Prevenar (Wyeth) 3.3.10 Prevnar/Prevenar Revenues, 2009 3.3.11 Prevnar/Prevenar/Prevnar Sales Forecast, 2010-2015 3.3.12 Polio/Pertussis/Hib Vaccines (Sanofi-Aventis) 3.3.13 Polio/Pertussis/Hib Vaccines (Sanofi- Aventis) Sales Forecast, 2010-2015 3.3.14 Infanrix/Pediarix (GlaxoSmithKline) 3.3.15 Infanrix/Pediarix Sales Forecast, 2010-2015 3.3.16 RotaTeq (Merck & Co/Sanofi Pasteur MSD) 3.3.17 RotaTeq Sales Forecast, 2010-2015 3.3.18 Rotarix (GSK) 3.3.19 Rotarix Sales Forecast, 2010-2015 3.4 Influenza Vaccines 3.4.1 Influenza Market Forecast 2010-2025 3.4.2 Influenza Market Forecast by Brand, 2010-2015 3.4.3 Influenza Vaccines Growth Driven by Pandemic Influence 3.4.4 Fluzone/Vaxigrip/Mutagrip (Sanofi-Aventis/Sanofi Pasteur MSD) 3.4.5 New Fluzone Formula for Elderly 3.4.6 Fluarix and FluLaval (GlaxoSmithKline) 3.5 Adult/Other Vaccines 3.5.1 Leading Adult/Other Vaccine Brands, 2009 3.5.2 Leading Adult/Other Vaccine Manufacturers, 2009 3.5.3 Adult/Other Vaccine Market Forecast, 2010-2025 3.5.4 Zostavax (Merck & Co/Sanofi Pasteur MSD) 3.5.5 Zostavax Sales Forecast, 2010-2015: a New Blockbuster? 3.5.6 Pneumovax (Merck & Co/Sanofi Pasteur MSD) 3.5.7 Pneumovax Sales Forecast, 2010-2015 3.5.8 Adacel (Sanofi-Aventis/Sanofi Pasteur MSD) 3.5.9 Adacel Market Forecast, 2010-2015 3.6 Prophylactic Cancer Vaccines 3.6.1 Leading Prophylactic Cancer Brands, 2009 3.6.2 Leading Prophylactic Cancer Vaccine Manufacturers, 2009 3.6.3 Prophylactic Cancer Vaccine Market Forecast, 2010-2025 3.6.4 Gardasil (Merck & Co./Sanofi Pasteur MSD/CSL) 3.6.5.Expanded Indications for Gardasil 3.6.6 Gardasil Sales Forecast 2010-2015 3.6.7 Cervarix (GlaxoSmithKline) 3.6.8 New Vaccine Blockbuster: Cervarix Sales Forecast, 2010-2015 3.7 Hepatitis Vaccines 3.7.1 Leading Hepatitis Vaccine Manufacturers, 2009 3.7.2 Hepatitis Vaccine Market Forecast, 2010-2025 3.7.3 GSK Hepatitis Vaccines 3.7.4 Havrix 3.7.5 Engerix-B 3.7.6 Twinrix/Ambirix 3.7.7 Merck & Co./Sanofi Pasteur MSD Hepatitis Vaccines 3.7.8 Vaqta/Avaxim 3.7.9 Recombivax HB/HBvaxPRO 3.7.10 Leading Hepatitis Vaccine Brand Forecasts, 2010-2025 3.8 Therapeutic Vaccines, 2010-2025 3.8.1 Rapid Growth for Therapeutic Vaccines 3.8.2 Most Therapeutic Vaccines are Not Registered Drugs 3.8.3 Grazax (ALK-Abelló) 4. Factors Influencing the Global Vaccines Industry and Market 4.1 SWOT Analysis of the Vaccines Market in 2010 4.2 Key Strengths of the Vaccines Sector 4.2.1 Vaccines are Important Agents with High Efficacy 4.2.2 New Vaccine Technologies 4.2.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines 4.2.2.2 New Types of Vaccine 4.2.2.3 New Adjuvants for Vaccines 4.2.2.4 New Vaccine Delivery Mechanisms and Formulations 4.2.2.5 Other Developments in Vaccine Technology 4.2.3 New High-Margin Vaccines 4.2.4 Vaccines Will Not Face Significant Generic Competition 4.2.5 Personalised Vaccines 4.3 The Vaccines Industry: Weaknesses 4.3.1 Vaccine Research and Development is Lengthy and Expensive 4.3.1.1 The Vaccine Research and Development Process 4.3.1.2 Vaccine Research and Development will be Outsourced to Emerging Markets 4.3.2 Vaccine Manufacturing 4.3.2.1 Vaccine Manufacturing has High Costs 4.3.2.2 China, India and Brazil Will Become Hubs for Manufacturing Paediatric Vaccines 4.3.3 Consolidation Among Vaccine Manufacturers 4.4 Opportunities for the Vaccines Sector 4.4.1 Vaccines for Diseases Currently Without a Vaccine 4.4.1.1 The Most Important Non-Vaccine-Preventable Diseases 4.4.1.2 Cancer 4.4.1.3 Dengue Fever 4.4.1.4 Enterohaemorrhagic Escherichia Coli (EHEC) 4.4.1.5 Epstein-Barr Virus (EBV) 4.4.1.6 Helicobacter Pylori Infections 4.4.1.7 Hepatitis C 4.4.1.8 Hepatitis E 4.4.1.9 HIV/AIDS 4.4.1.10 Malaria 4.4.1.11 Nosocomial Infections 4.4.1.12 Clostridium Difficile 4.4.1.13 Staphylococcus Spp. Bacteria 4.4.1.14 Other Nosocomial Infections 4.4.1.15 Respiratory Infections 4.4.1.16 Roundworm and Hookworm Infections 4.4.1.17 Sexually-Transmitted Diseases 4.4.1.18 Chlamydia 4.4.1.19 Herpes Virus Simplex Virus 4.4.1.20 Other Sexually-Transmitted Diseases 4.4.1.21 Tobacco 4.4.1.22 West Nile Virus Infections 4.4.2 Improved Vaccines for Partially Vaccine-Preventable Diseases 4.4.2.1 Vaccines Effective Against More Strains 4.4.2.2 Towards a Universal Influenza Vaccine 4.4.2.3 The Need for an Improved Tuberculosis Vaccines 4.4.3 Biodefence 4.4.4 The Future for Bioterrorism Vaccines 4.4.5 Pandemic-Preparedness 4.4.6 Changing World Demographics 4.4.6.1 Population Increase 4.4.6.2 Emerging-Market Economies 4.5 Threats Facing the Vaccines Sector 4.5.1 The Anti-Vaccine Movement 4.5.1.1 Misinformation about Side-Effects of Vaccines 4.5.1.2 MMR in the UK 4.5.1.3 Controversy Surrounding Mercury-Containing Vaccines 4.5.1.4 Campaigns Against Cervical Cancer Vaccines 4.5.1.5 Consequences of Anti-Vaccine Campaigns 4.5.2 Vaccines in the Developing World 4.5.2.1 Vaccine Distribution Networks 4.5.2.2 Vaccine Costs in Developing Countries 4.5.2.3 Improving Access to Vaccines in the Developing World 5. The Vaccines R&D Pipeline 5.1 The Most-Promising Sectors of the Vaccines R&D Pipeline 5.2 Paediatric Vaccines Pipeline 5.2.1 Paediatric Pipeline Vaccines Will Address Key Unmet Needs, 2010-2015 5.2.2 Synflorix (GlaxoSmithKline) 5.2.3 Prevnar 13 (Wyeth) 5.2.4 Menactra Toddler (Sanofi-Aventis) 5.2.5 Menveo (Novartis) 5.2.6 MenACWY-TT (GlaxoSmithKline) 5.2.7 Menhibrix (GlaxoSmithKline) 5.2.8 Hexaxim & Unifive (Sanofi-Aventis) 5.2.9 MenB (Novartis) 5.2.10 Meningitis B Vaccine (Wyeth) 5.2.11 ORV 116E (Bharat Biotech) 5.2.12 Streptococcus Pneumoniae Vaccine (Intercell) 5.3 Influenza Vaccines Pipeline 5.3.1 Key Developments in Influenza Vaccines, 2010-2015 5.3.2 Cell Culture Influenza Vaccines 5.3.2.1 The Switch from Eggs 5.3.2.2 Optaflu (Novartis) 5.3.2.3 FluBlok (Protein Sciences/UMN Pharma) 5.3.2.4 Influvac TC (Solvay) 5.3.2.5 Vero-Cell Technology (Baxter/DynPort) 5.3.2.6 Per.C6 (Sanofi-Aventis/Crucell/Lonza) 5.3.2.7 VLP Vaccines (Novavax) 5.3.3 Pipeline Pandemic H5N1 (Avian) Influenza Vaccines 5.3.3.1 Pandemic and Pre-Pandemic H5N1 Vaccines 5.3.3.2 Celvapan (Baxter) 5.3.3.3 Panvax (CSL) 5.3.3.4 GlaxoSmithKline's H5N1 Vaccines 5.3.3.5 Novartis' Pre-Pandemic Vaccines 5.3.3.6 Pandemic H5N1 VLP Influenza Vaccine (Novavax) 5.3.3.7 Sanofi-Aventis' H5N1 Influenza Vaccine Programme 5.3.3.8 Panflu (H5N1 Vaccine, Sinovac) 5.3.4 Pipeline Pandemic Novel H1N1 (Swine Flu) Influenza Vaccines 5.3.4.1 GlaxoSmithKline 5.3.4.2 Novartis 5.3.4.3 Novavax 5.3.4.4 Sanofi-Aventis 5.3.4.5 Sinovac 5.3.4.6 Vaxine 5.3.5 Novel Delivery Systems for Influenza Vaccines 5.3.6 New Adjuvants for Influenza Vaccines 5.3.6.1 Fluad (Novartis) 5.3.6.2 Grippol Neo (Solvay/Petrovax) 5.3.6.3 Iscomatrix Adjuvant (CSL) 5.3.6.4 Pandemic Influenza Vaccine Enhancement Patch (Intercell) 5.3.6.5 Advax (Vaxine) 5.3.6.6 Vaxfectin (Vical) 5.3.6.7 VaxiSome (NasVax) 5.3.7 Potential Universal Influenza Vaccine 5.3.7.1 ACAM-Flu-A (Sanofi-Aventis) 5.3.7.2 Multimeric Universal Influenza Vaccine (Biondvax) 5.4 Other/Adult Vaccines Pipeline 5.4.1 Key Developments in Adult/Other Vaccines, 2010-2015 5.4.2 What are the Prospects for new Adult Vaccines from 2015 to 2025? 5.4.3 Ixiaro (Novartis/Intercell) 5.4.4 Imojev (Sanofi-Aventis) 5.4.5 Adenovirus Vaccines (Teva) 5.4.6 Flavinum (Crucell) 5.4.7 Expanded Indications for Adacel 5.4.8 Simplirix (GlaxoSmithKline) 5.4.9 ALVAC-HIV (Sanofi-Aventis) 5.4.10 Mosquirix (GlaxoSmithKline) 5.4.11 rPA 102 (Anthrax Vaccine, Emergent BioSolutions) 5.4.12 SparVax (PharmAthene) 5.4.13 rF1V Plague Vaccine (DynPort) 5.4.14 Imvamune (Bavarian Nordic) 5.4.15 ACE393/Campylobacter Jejuni Vaccine (ACE Biosciences/Biotecnol) 5.4.16 CholeraGarde (Celldex/Vaccine Technologies) 5.4.17 Cytomegalovirus Vaccine (Sanofi-Aventis) 5.4.18 Dengue Fever Vaccine (Sanofi-Aventis) 5.4.19 Dengue Virus Vaccine (GlaxoSmithKline) 5.4.20 Escherichia Coli Travellers' Diarrhoea Vaccine Patch (Intercell) 5.4.21 tgAAC09 (Targeted Genetics) 5.4.22 VRC-HIVADV014-00VP (GenVec/NIAID Vaccine Research Center) 5.4.23 ACAM-Cdiff (Sanofi-Aventis) 5.4.24 Pseudomonas Aeruginosa Vaccines, (Intercell and Novartis) 5.4.25 V 710 (Staphylococcus Aureus Vaccine (Merck & Co./Intercell) 5.4.26 PentaStaph (Nabi Biopharmaceuticals/GlaxoSmithKline) 5.4.27 Herpes Zoster Vaccine (GlaxoSmithKline) 5.4.28 GSK M72/Tuberculosis Vaccine (GlaxoSmithKline) 5.4.29 MVA85A/AERAS-485 (Tuberculosis Vaccine, Emergent BioSolutions) 5.4.30 Ty800 (Oral Typhoid Vaccine, Celldex) 5.4.31 Typhoid Vaccine (Emergent Biosolutions) 5.4.32 West Nile Vaccine (Sanofi-Aventis) 5.5 Hepatitis Vaccines Pipeline 5.5.1 Heplisav (Dynavax) 5.5.2 V419 (Paediatric Hepatitis B Vaccine (Merck & Co) 5.5.3 Prophylactic Hepatitis B Vaccine (Vaxine) 5.5.4 Hepatitis E Vaccine (GlaxoSmithKline) 5.6 Prophylactic Cancer Vaccines Pipeline 5.6.1 V503 (Nine-Valent Human Papillomavirus Vaccine, Merck & Co.) 5.6.2 Epstein-Barr Virus Vaccine (AstraZeneca) 5.6.3 Helicobacter Pylori Vaccine (Novartis) 5.7 Therapeutic Vaccines Pipeline 5.7.1 Therapeutic Vaccines for Cancer 5.7.1.1 Provenge/Sipuleucel-T (Dendreon) 5.7.1.2 BiovaxID (Accentia Biopharmaceuticals) 5.7.1.3 MVax (Avax Technologies) 5.7.1.4 MAGE-A3 ASCI (GlaxoSmithKline/Ludwig Institute of Cancer Research) 5.7.1.5 Stimuvax (Merck KGaA/Oncothyreon) 5.7.1.6 TroVax (Oxford BioMedica) 5.7.1.7 OncoVAX (Vaccinogen/Intracel) 5.7.1.8 Allovectin-7 (Vical/AnGes MG) 5.7.1.9 PF-4948568/CDX-110 (Pfizer/Celldex) 5.7.1.10 GV1001 (Pharmexa) 5.7.2 Therapeutic Vaccines for Hepatitis 5.7.2.1 Therapeutic Hepatitis B Vaccine (Emergent Biosolutions) 5.7.2.2 GI-5005/Hepatitis C Treatment Vaccine (GlobeImmune) 5.7.2.3 Hepatitis C Vaccine (Intercell/Novartis) 5.7.3 Therapeutic Vaccines for HIV Infection 5.7.4 Therapeutic Vaccines for Other Viral Infections 5.7.4.1 TG 4001/R3484 (MVA-HPV-IL2/HPV Vaccine (Transgene/Roche) 5.7.4.2 Cytomegalovirus Therapeutic Vaccine (Vical) 5.7.5 Therapeutic Addiction Vaccines 5.7.5.1 Addiction Vaccines Will Target Nicotine and Drug Dependency 5.7.5.2 NicVAX (Nabi Biopharmaceuticals) 5.7.5.3 NIC002 (Novartis/Cytos Biotechnology) 5.7.5.4 TA-NIC (Celtic Pharma) 5.7.5.5 Niccine (Independent Pharmaceutica) 5.7.5.6 TA-CD (Celtic Pharma) 5.7.6 Therapeutic Allergy Vaccines 5.7.6.1 House Dust Mite Allergy Vaccine (ALK-Abelló/Schering-Plough) 5.7.7 Therapeutic Vaccines for Chronic Disease 5.7.7.1 Alzheimer's Disease 6. Interviews with Relevant Experts 6.1 Dr David S. Fedson, MD, Formerly Professor of Medicine, University of Virginia School of Medicine; Former Director of Medical Affairs, Aventis Pasteur MSD 6.2 Dr Raafat E. F. Fahim, Ph.D., President and Chief Executive Officer, Nabi Biopharmaceuticals 6.3 Dr Tamar Ben-Yedida, Director of R&D, Biondvax Pharmaceuticals 7. Conclusions of this Study 7.1 The Vaccines Market will Experience Strong Growth from 2010 to 2025 7.2 The Balance of Power within the Vaccines Market will Shift 7.3 Public Misunderstanding of the Dangers of Vaccination will Continue to Threaten Market Growth 7.4 Global Vaccines Market: Summary [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Vaccine-Preventable Disease Statistics Table 2.2 Influenza Virus Types Table 3.1 Definition of Vaccine Types Used in this Report Table 3.2 Vaccine Sales by Type, 2009 Table 3.3 Vaccine Sales by Brand, 2009 Table 3.4 Vaccine Sales by Manufacturer, 2009 Table 3.5 Global Vaccine Market: Sales Forecast, 2010-2025 Table 3.6 Global Vaccine Market: Sales Forecast by Vaccine Type, 2010-2025 Table 3.7 Global Vaccine Market: Sales Forecast by Vaccine Type, 2015-2025 Table 3.8 Paediatric Vaccine Sales by Brand, 2009 Table 3.9 Paediatric Vaccine Sales by Manufacturer, 2009 Table 3.10 Paediatric Vaccine Market: Sales Forecast, 2010-2025 Table 3.11 Varivax/M-M-R-II/ProQuad: Sales Analysis, 2009 Table 3.12 Leading Paediatric Vaccines: Sales Forecasts, 2010-2015 Table 3.13 Example Brands for Polio/Pertussis/Hib Vaccines, 2009 Table 3.14 Brands in the Infanrix/Pediarix Range of Vaccines, 2009 Table 3.15 Influenza Vaccine Market: Sales Forecast, 2010-2025 Table 3.16 Leading Influenza Brands: Sales Forecasts, 2010-2025 Table 3.17 Adult/Other Vaccine Sales by Brand, 2009 Table 3.18 Adult/Other Vaccine Sales by Manufacturer, 2009 Table 3.19 Adult/Other Vaccines: Sales Forecast, 2010-2025 Table 3.20 Leading Adult/Other Vaccine Brands: Sales Forecasts, 2010-2015 Table 3.21 Prophylactic Cancer Vaccines: Sales by Manufacturer, 2009 Table 3.22 Prophylactic Cancer Vaccine Market: Sales Forecast, 2010-2025 Table 3.23 Prophylactic Cancer Vaccine Brands: Sales Forecasts, 2010-2025 Table 3.24 Hepatitis Vaccine Sales by Manufacturer, 2009 Table 3.25 Hepatitis Vaccine Market: Sales Forecast, 2010-2025 Table 3.26 Leading Hepatitis Vaccine Manufacturers: Sales Forecasts, 2010-2015 Table 3.27 Therapeutic Vaccines Market: Sales Forecast, 2010-2025 Table 4.1 SWOT Analysis for the Global Vaccines Market, 2010 Table 4.2 Selected Diseases Currently Without a Vaccine, 2010 Table 5.1 Key Pipeline Paediatric Vaccines, 2010 Table 5.2 Key Cell-Culture Influenza Vaccines, 2010 Table 5.3 Key Pandemic H5N1 (Avian) Influenza Vaccines, 2010 Table 5.4 Key Novel H1N1 Influenza (Swine Flu) Vaccines, 2010 Table 5.5 Key Pipeline Influenza Vaccines with Novel Delivery Systems, 2010 Table 5.6 Key Pipeline Influenza Vaccines with Novel Adjuvants, 2010 Table 5.7 Key Pipeline Other/Adult Vaccines: Phase III & Later, 2010 Table 5.8 Key Pipeline Other/Adult Vaccines: Phase II, 2010 Table 5.9 Key Pipeline Other/Adult Vaccines: Phase I, 2010 Table 5.10 Key Pipeline Hepatitis Vaccines, 2010 Table 5.11 Key Pipeline Prophylactic Cancer Vaccines, 2010 Table 5.12 Key Pipeline Therapeutic Cancer Vaccines, 2010 Table 5.13 Key Pipeline Therapeutic Hepatitis Vaccines, 2010 Table 5.14 Key Pipeline Therapeutic HIV/AIDS Vaccines, 2010 Table 5.15 Key Pipeline Therapeutic Addiction Vaccines, 2010 Table 5.16 Key Pipeline Therapeutic Chronic Disease Vaccines, 2010 Figure 3.1 Vaccine Sales by Type, 2009 Figure 3.2 Vaccine Sales by Brand, 2009 Figure 3.3 Vaccine Sales by Manufacturer, 2009 Figure 3.4 Global Vaccine Market: Sales Forecast 2010-2025 Figure 3.5 Global Vaccine Market: Sales Forecast by Vaccine Type, 2010-2025 Figure 3.6 Global Vaccine Market: Sales Shares by Vaccine Type, 2010-2025 Figure 3.7 Paediatric Vaccine Sales by Brand, 2009 Figure 3.8 Paediatric Vaccine Sales by Manufacturer, 2009 Figure 3.9 Paediatric Vaccine Market: Sales Forecast, 2010-2025 Figure 3.10 Varivax/M-M-R II/Proquad: Sales Forecast, 2010-2015 Figure 3.11 Prevenar/Prevnar/Prevnar 13: Sales Forecast, 2010-2015 Figure 3.12 Polio/Pertussis/Hib Vaccines (Sanofi-Aventis): Sales Forecast, 2010-2015 Figure 3.13 Infanrix/Pediarix Market: Sales Forecast, 2010-2015 Figure 3.14 Rotateq and Rotarix Market: Sales Forecast, 2010-2015 Figure 3.15 Influenza Vaccine Market: Sales Forecast, 2010-2025 Figure 3.16 Leading Influenza Vaccine Market: Sales Forecast, 2009-2015 Figure 3.17 Adult/Other Vaccine Sales by Manufacturer, 2009 Figure 3.18 Adult/Other Vaccines: Sales Forecast, 2009-2025 Figure 3.19 Zostavax Sales Forecast, 2009-2015 Figure 3.20 Pneumovax Sales Forecast, 2009-2015 Figure 3.21 Adacel Sales Forecast, 2009-2015 Figure 3.22 Prophylactic Cancer Vaccine Sales by Manufacturer, 2009 Figure 3.23 Prophylactic Cancer Vaccine Market: Sales Forecast, 2009-2025 Figure 3.24 Gardasil Sales Forecast, 2009-2015 Figure 3.25 Cervarix Sales Forecast, 2009-2015 Figure 3.26 Hepatitis Vaccine Market: Sales Forecast, 2009-2025 Figure 3.27 Hepatitis Vaccine Leading Brands: Sales Forecast, 2009-2015 Figure 3.28 Therapeutic Vaccine Market: Sales Forecast, 2009-2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
